Tech Company Financing Transactions

Nuvig Therapeutics Funding Round

On 12/5/2024, Nuvig Therapeutics received $161 million in Series B funding from Blue Owl Capital, Norwest Venture Partners and Sanofi Ventures.

Transaction Overview

Company Information

Company Status

Private & Independent

Industry

Biopharmaceutical

Mailing Address

1775 Woodside Rd. 201
Redwood City, CA 94061
USA

Phone

Undisclosed

Website

www.nuvigtherapeutics.com

Email Address

[email protected]

Overview

Our mission is to bring innovative and transformational therapies to patients with chronic autoimmune diseases, via induction of mechanisms that restore immune homeostasis. Our first product candidate is a recombinant protein that selectively activates a class of immune regulatory receptors that are naturally involved in rebalancing immune function following inflammation.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Pamela Conley

        

Vice President

Greg Coffey

        

VP - Operations

Heidi Remsberg

        

Browse more venture capital transactions:

Prev: 12/5/2024: BRM venture capital transaction
Next: 12/5/2024: syte venture capital transaction

Share this article

Where The Data Comes From

We report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary